Silence Therapeutics Funding: $120M Raised, Series B (2024)
Silence Therapeutics is based in London, United Kingdom. It has raised $120M in total funding. Latest round: Series B.
Silence Therapeutics funding overview
Silence Therapeutics is based in London, United Kingdom. Silence Therapeutics has raised $120M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in February 2024. The round record for Silence Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include 5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest Ltd, Redmile Group, TCGX and 1 others. 7 distinct backers are named across the disclosed rounds.
Silence Therapeutics at a glance
Total raised
$120M
Latest round
Series B
Latest round date
February 2024
Headquarters
London, United Kingdom
Notable investors
5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest Ltd, Redmile Group, TCGX, Vivo Capital
Frequently asked about Silence Therapeutics funding
How much has Silence Therapeutics raised?
Silence Therapeutics has raised $120M in total disclosed funding across the rounds on record.
Who has invested in Silence Therapeutics?
5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest Ltd, Redmile Group, TCGX are named among the investors backing Silence Therapeutics.
What was the latest Silence Therapeutics funding round?
The most recent disclosed round is a Series B, announced in February 2024.
Where is Silence Therapeutics based?
Silence Therapeutics is based in London, United Kingdom.
When did Silence Therapeutics last raise?
The last disclosed Silence Therapeutics round closed in February 2024 at Series B.
Silence Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in London below to benchmark round size and investor mix.
